AZTR
Azitra·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Consensus Rating "Strong Buy"
Significant Revenue Decline
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AZTR
Azitra Inc
A pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases
Biological Technology
01/02/2014
06/16/2023
American Stock Exchange
12
12-31
Common stock
21 Business Park Drive, Branford, CT 06405
--
Azitra Inc was incorporated under the laws of the State of Delaware on January 2, 2014. The company is an early-stage clinical biopharmaceutical company focused on the development of innovative therapies for precision dermatology using engineered proteins and topical living biological therapy products. The company has established a proprietary platform that includes a microbial library consisting of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic properties. The platform is enhanced by artificial intelligence and machine learning technology that analyzes, predicts and helps screen strain libraries of drug-like molecules.
Company Financials
EPS
AZTR has released its 2025 Q3 earnings. EPS was reported at -0.67, versus the expected -0.77, beating expectations. The chart below visualizes how AZTR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
